Finding new targets for immunotherapy in triple-negative breast cancer
Official title: Identifying Chemo-Neoepitopes for Immunotherapy Interventions Against Triple-Negative Breast Cancer
Funded at Roswell Park Cancer Institute Corp · NIH-10946981 · Data updated 2026-11-12
This study is looking for ways to make treatments better for people with advanced triple-negative breast cancer by finding special markers on tumors that can help the immune system fight the cancer more effectively, especially after chemotherapy.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Roswell Park Cancer Institute Corp NIH-funded |
| Lab location | 1 site (Buffalo, United States) |
| Project start | June 1, 2024 |
| Project end | May 31, 2026 |
| Funding year | 2024 |
| Award (this year) | $460,977 |
| NIH project number | 1R21CA286342-01A1 |
| Project ID | NIH-10946981 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with advanced triple-negative breast cancer who are undergoing or have undergone chemotherapy.
✕Less likely to help
Patients with non-triple-negative breast cancer or those who are not receiving chemotherapy may not benefit from this research.
What this research studies
This research focuses on improving treatment options for patients with advanced triple-negative breast cancer (TNBC) by identifying specific tumor antigens that can enhance the effectiveness of immunotherapy. The approach involves analyzing how chemotherapy affects cancer cells and generates new antigens that can be recognized by the immune system. By understanding these mechanisms, the research aims to develop better immunotherapy strategies that could lead to improved patient outcomes.
Why it matters
Potential benefit: If successful, this research could lead to more effective immunotherapy treatments for patients with triple-negative breast cancer, potentially extending survival rates.
How similar studies have gone: Previous research has shown promising results in enhancing immunotherapy effectiveness through the identification of tumor antigens, suggesting that this approach could lead to significant advancements in treatment.
Where this research is happening
-
Roswell Park Cancer Institute Corp
Buffalo, United States Active
Researchers
- Principal investigator: Ionov, Yurij — Roswell Park Cancer Institute Corp
- Study coordinator: Ionov, Yurij
Related research
Other NIH-funded projects on the same topics.
-
Rac-enhanced CAR-Macrophages against TNBC
A new cell therapy approach uses engineered macrophages with a CAR and Rac2 activation to target and kill triple-negative breast cancer cells expressing CSPG4.
-
Determinants of Response to DNA-Damaging Radiation and Immunotherapy in Triple-Negative Breast Cancer
This grant explores why some people with triple-negative breast cancer respond to a combo of radiation, chemotherapy, and immunotherapy and why others don’t, to guide more personalized treatment.
-
New immunotherapy combo for hard-to-treat triple-negative breast cancer
Aims to test a combination immunotherapy with JNK inhibitors to improve treatment for people with triple-negative breast cancer.
-
Reprogrammed exosome immunotherapy for triple-negative breast cancer
A new treatment approach uses engineered exosomes to stimulate the immune system to fight triple-negative breast cancer in patients.
-
Engineered CD4+ T cells targeting KK‑LC‑1 for triple‑negative breast cancer
This project creates engineered CD4+ T cells that recognize the KK‑LC‑1 tumor antigen to help people with HLA‑DR13-positive triple‑negative breast cancer.
-
Why some triple-negative breast cancers respond to radiation plus immunotherapy and others resist
This project looks at whether patterns of tumor cell death and immune signals can predict and improve responses to radiation combined with anti-PD1 immunotherapy for people with early-stage triple-negative breast cancer that has spread to lymph nodes.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.